Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00577720 · ClinicalTrials.gov registry record · Phase 2
Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate
A Phase 2 study of Postmenopausal Women, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
- 6
- Study locations
NCT00577720: Completed Phase 2 study of Postmenopausal Women, sponsored by Warner Chilcott.
NCT00577720 is a Phase 2 study of Postmenopausal Women that has completed, run by Warner Chilcott. The registered enrollment target is 181 participants, above the 55-participant average among 4 other Postmenopausal Women trials with a reported enrollment target (229% higher). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00577720, a Phase 2 study of Postmenopausal Women, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
- 6
- Study locations
Study Summary
To compare the efficacy 50 mg delayed-release risedronate tablet, dosed immediately after breakfast, to a 35 mg immediate-release tablet, administered according to labeling instructions.
Conditions Studied
Interventions
- DRUG risedronate
Study Locations (6)
Florida
- Research Facility - Gainsville
- Research Facility - Miami
Texas
- Research Site - Dallas
- Research Facility - San Antonio
California
- Research Facility - Costa Mesa
Hawaii
- Research Facility - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
What the finished NCT00577720 record still lists
NCT00577720 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, above the 55-participant average among 4 other Postmenopausal Women trials with a reported enrollment target (229% higher).
The record links to 1 condition, with Postmenopausal Women appearing as the primary indexed condition, and to 1 intervention - of which risedronate is the first listed.
NCT00577720 lists 6 locations in 4 states (Florida, Texas, California).
Frequently Asked Questions
What is clinical trial NCT00577720 about?
NCT00577720 is a clinical study titled "Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate". To compare the efficacy 50 mg delayed-release risedronate tablet, dosed immediately after breakfast, to a 35 mg immediate-release tablet, administered according to labeling instructions.
What is the current status of trial NCT00577720?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2006-07. Estimated completion is 2007-01.
What conditions does trial NCT00577720 study?
This clinical trial studies the following conditions: Postmenopausal Women.
What interventions are being tested in trial NCT00577720?
The interventions under investigation include: risedronate (DRUG).
Who is sponsoring clinical trial NCT00577720?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00577720 being conducted?
This trial has 6 study locations across California, Florida, Hawaii, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postmenopausal Women
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia